Sorrento Files IND for STI-1499 (COVI-GUARD) in Patients Hospitalized with COVID-19

 Sorrento Files IND for STI-1499 (COVI-GUARD) in Patients Hospitalized with COVID-19

Sorrento Files IND for STI-1499 (COVI-GUARD) in Patients Hospitalized with COVID-19

Shots:

  • Sorrento has filed an IND for STI-1499 in patients hospitalized with COVID-19. In preclinical studies, STI-1499 has demonstrated 100% neutralizing effect (in vitro) against the highly contagious D614G mutant strain at a low dose
  • Additionally, animal model data confirms the neutralizing profile and high potency of Ab, expected effective dose in human to be at least 5 times lower than current known Abs being assessed in other active trials
  • Sorrento has initiated cGMP manufacturing to produce 50,000 doses, expected to be available by the end of 2020, in anticipation of a potential EUA

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Blogger

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post